{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:43:01Z","timestamp":1792755781998,"version":"4.5.0"},"reference-count":134,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Drugs that modulate the GABA<jats:sub>A<\/jats:sub> receptor are widely used in clinical practice for both the long-term management of epilepsy and emergency seizure control. In addition to older medications that have well-defined roles for the treatment of epilepsy, recent discoveries into the structure and function of the GABA<jats:sub>A<\/jats:sub> receptor have led to the development of newer compounds designed to maximise therapeutic benefit whilst minimising adverse effects, and whose position within the epilepsy pharmacologic armamentarium is still emerging. Drugs that modulate the GABA<jats:sub>A<\/jats:sub> receptor will remain a cornerstone of epilepsy management for the foreseeable future and, in this article, we provide an overview of the mechanisms and clinical efficacy of both established and emerging pharmacotherapies.<\/jats:p>","DOI":"10.3389\/fphar.2024.1341472","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T05:49:41Z","timestamp":1708494581000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Established and emerging GABAA receptor pharmacotherapy for epilepsy"],"prefix":"10.3389","volume":"15","author":[{"given":"Robert J.","family":"Richardson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Petrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bryson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/s41467-022-29280-x","article-title":"Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies","volume":"13","author":"Absalom","year":"2022","journal-title":"Nat. Commun."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15932","article-title":"GABAA receptors in epilepsy: elucidating phenotypic divergence through functional analysis of genetic variants","author":"Absalom","year":"2023","journal-title":"J. Neurochem"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/brain\/awab391","article-title":"Gain-of-function variants in GABRD reveal a novel pathway for neurodevelopmental disorders and epilepsy","volume":"145","author":"Ahring","year":"2022","journal-title":"Brain"},{"key":"B4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa002141","article-title":"A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus","volume":"345","author":"Alldredge","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B134","doi-asserted-by":"publisher","first-page":"107014","DOI":"10.1016\/j.eplepsyres.2022.107014","article-title":"Post hoc analysis of a phase 3 study for treatment of uncontrolled focal seizures: Adjunctive cenobamate dose and seizure reduction by baseline seizure frequency","volume":"186","author":"Aboumatar","year":"2022","journal-title":"Epilepsy Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/0140-6736(93)91255-k","article-title":"Vigabatrin in infantile spasms--why add on?","volume":"341","author":"Appleton","year":"1993","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1111\/j.1528-1157.1999.tb02049.x","article-title":"Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms","volume":"40","author":"Appleton","year":"1999","journal-title":"Epilepsia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/ng0501-46","article-title":"First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene","volume":"28","author":"Baulac","year":"2001","journal-title":"Nat. Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/s0028-3908(02)00172-7","article-title":"The influence of subunit composition on the interaction of neurosteroids with GABA(A) receptors","volume":"43","author":"Belelli","year":"2002","journal-title":"Neuropharmacology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"12757","DOI":"10.1523\/JNEUROSCI.3340-09.2009","article-title":"Extrasynaptic GABAA receptors: form, pharmacology, and function","volume":"29","author":"Belelli","year":"2009","journal-title":"J. Neurosci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1600-0404.2011.01596.x","article-title":"Mechanism of action of vigabatrin: correcting misperceptions","author":"Ben-Menachem","year":"2011","journal-title":"Acta Neurol. Scand."},{"key":"B11","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/s0014-5793(98)00803-5","article-title":"Pharmacology of recombinant gamma-aminobutyric acidA receptors rendered diazepam-insensitive by point-mutated alpha-subunits","volume":"431","author":"Benson","year":"1998","journal-title":"FEBS Lett."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1111\/epi.16726","article-title":"Progress report on new antiepileptic drugs: a summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development","volume":"61","author":"Bialer","year":"2020","journal-title":"Epilepsia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1111\/epi.17376","article-title":"Progress report on new antiepileptic drugs: a summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II. Drugs in more advanced clinical development","volume":"63","author":"Bialer","year":"2022","journal-title":"Epilepsia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1124\/pr.54.2.247","article-title":"International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function","volume":"54","author":"Bowery","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"CD013028","DOI":"10.1002\/14651858.CD013028.pub2","article-title":"Clonazepam monotherapy for treating people with newly diagnosed epilepsy","volume":"2","author":"Brigo","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/epi.12027","article-title":"Current position of phenobarbital in epilepsy and its future","volume":"53","author":"Brodie","year":"2012","journal-title":"Epilepsia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jnc.15769","article-title":"Fundamental Neurochemistry Review: GABA(A) receptor neurotransmission and epilepsy: principles, disease mechanisms and pharmacotherapy","volume":"165","author":"Bryson","year":"2023","journal-title":"J. Neurochem."},{"key":"B18","first-page":"1284","article-title":"Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor","volume":"280","author":"Carter","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"616298","DOI":"10.3389\/fnins.2020.616298","article-title":"Looking for novelty in an \"old\" receptor: recent advances toward our understanding of GABA(A)rs and their implications in receptor pharmacology","volume":"14","author":"Castellano","year":"2020","journal-title":"Front. Neurosci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"108035","DOI":"10.1016\/j.pharmthera.2021.108035","article-title":"GABAkines - advances in the discovery, development, and commercialization of positive allosteric modulators of GABA(A) receptors","volume":"234","author":"Cerne","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e3000157","DOI":"10.1371\/journal.pbio.3000157","article-title":"Multiple functional neurosteroid binding sites on GABAA receptors","volume":"17","author":"Chen","year":"2019","journal-title":"PLoS Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/s0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1124\/jpet.117.244673","article-title":"Genetic and molecular regulation of extrasynaptic GABA-A receptors in the brain: therapeutic insights for epilepsy","volume":"364","author":"Chuang","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/brain\/awaa045","article-title":"In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy","volume":"143","author":"Colasante","year":"2020","journal-title":"Brain"},{"key":"B26","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/epi.12561","article-title":"Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years","volume":"55","author":"Conry","year":"2014","journal-title":"Epilepsia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.celrep.2017.09.025","article-title":"An essential role for the tetraspanin LHFPL4 in the cell-type-specific targeting and clustering of synaptic GABA(A) receptors","volume":"21","author":"Davenport","year":"2017","journal-title":"Cell Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/s1059-1311(95)80003-4","article-title":"Mechanisms of action of antiepileptic drugs","volume":"4","author":"Davies","year":"1995","journal-title":"Seizure"},{"key":"B29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1528-1157.1999.tb01991.x","article-title":"Dose-Response Study of Vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures","volume":"40","author":"Dean","year":"1999","journal-title":"Epilepsia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/s0896-6273(02)01053-x","article-title":"Paracrine intercellular communication by a Ca2+- and SNARE-independent release of GABA and glutamate prior to synapse formation","volume":"36","author":"Demarque","year":"2002","journal-title":"Neuron"},{"key":"B31","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/0306-3623(95)02147-7","article-title":"1,4-Benzodiazepine derivatives as anticonvulsant agents in DBA\/2 mice","volume":"27","author":"De Sarro","year":"1996","journal-title":"Gen. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1177\/0883073810365103","article-title":"Vigabatrin for the treatment of infantile spasms: final report of a randomized trial","volume":"25","author":"Elterman","year":"2010","journal-title":"J. Child. Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1212\/wnl.57.8.1416","article-title":"Randomized trial of vigabatrin in patients with infantile spasms","volume":"57","author":"Elterman","year":"2001","journal-title":"Neurology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1060949","DOI":"10.3389\/fpsyt.2022.1060949","article-title":"GABA(A) receptor subtypes and benzodiazepine use, misuse, and abuse","volume":"13","author":"Engin","year":"2022","journal-title":"Front. Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.tips.2018.04.003","article-title":"An emerging circuit pharmacology of GABA(A) receptors","volume":"39","author":"Engin","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1046\/j.1460-9568.1999.00423.x","article-title":"GABAC receptor rho subunits are heterogeneously expressed in the human CNS and form homo- and heterooligomers with distinct physical properties","volume":"11","author":"Enz","year":"1999","journal-title":"Eur. J. Neurosci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0079-6123(06)60005-8","article-title":"The cellular, molecular and ionic basis of GABA(A) receptor signalling","volume":"160","author":"Farrant","year":"2007","journal-title":"Prog. Brain Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrn1625","article-title":"Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors","volume":"6","author":"Farrant","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.neuroimage.2006.05.059","article-title":"A GABAA receptor mutation causing generalized epilepsy reduces benzodiazepine receptor binding","volume":"32","author":"Fedi","year":"2006","journal-title":"Neuroimage"},{"key":"B40","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/epi.17441","article-title":"A randomized phase 2b efficacy study in patients with seizure episodes with a predictable pattern using Staccato\u00ae alprazolam for rapid seizure termination","volume":"64","author":"French","year":"2023","journal-title":"Epilepsia"},{"key":"B41","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1212\/wnl.46.1.54","article-title":"A double-blind, placebo-controlled study of vigabatrin three g\/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort","volume":"46","author":"French","year":"1996","journal-title":"Neurology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/epi.16279","article-title":"Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants","volume":"60","author":"French","year":"2019","journal-title":"Epilepsia"},{"key":"B43","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.neuron.2017.12.038","article-title":"Clptm1 limits forward trafficking of GABA(A) receptors to scale inhibitory synaptic strength","volume":"97","author":"Ge","year":"2018","journal-title":"Neuron"},{"key":"B44","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1113\/jphysiol.1995.sp021070","article-title":"Dependence of the GABAA receptor gating kinetics on the alpha-subunit isoform: implications for structure-function relations and synaptic transmission","volume":"489","author":"Gingrich","year":"1995","journal-title":"J. Physiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa0902014","article-title":"Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy","volume":"362","author":"Glauser","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.neuron.2007.11.002","article-title":"Activation of GABAA receptors: views from outside the synaptic cleft","volume":"56","author":"Glykys","year":"2007","journal-title":"Neuron"},{"key":"B47","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1152\/jn.00066.2014","article-title":"Development of dendritic tonic GABAergic inhibition regulates excitability and plasticity in CA1 pyramidal neurons","volume":"112","author":"Groen","year":"2014","journal-title":"J. Neurophysiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e1786","DOI":"10.1212\/WNL.0000000000007271","article-title":"Photosensitive epilepsy: robust clinical efficacy of a selective GABA potentiator","volume":"92","author":"Gurrell","year":"2019","journal-title":"Neurology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1111\/cns.13927","article-title":"Pronounced antiseizure activity of the subtype-selective GABA(A) positive allosteric modulator darigabat in a mouse model of drug-resistant focal epilepsy","volume":"28","author":"Gurrell","year":"2022","journal-title":"CNS Neurosci. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1126\/science.aax5719","article-title":"Shisa7 is a GABA(A) receptor auxiliary subunit controlling benzodiazepine actions","volume":"366","author":"Han","year":"2019","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.tins.2020.10.011","article-title":"Regulation of GABA(A)rs by transmembrane accessory proteins","volume":"44","author":"Han","year":"2021","journal-title":"Trends Neurosci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1086\/338710","article-title":"Truncation of the GABA(A)-receptor gamma2 subunit in a family with generalized epilepsy with febrile seizures plus","volume":"70","author":"Harkin","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/s0896-6273(00)80379-7","article-title":"Tonic synaptic inhibition modulates neuronal output pattern and spatiotemporal synaptic integration","volume":"19","author":"Hausser","year":"1997","journal-title":"Neuron"},{"key":"B54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.pharmthera.2007.03.011","article-title":"Neurosteroid binding sites on GABA(A) receptors","volume":"116","author":"Hosie","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.nbd.2014.04.015","article-title":"Three epilepsy-associated GABRG2 missense mutations at the \u03b3+\/\u03b2-interface disrupt GABAA receptor assembly and trafficking by similar mechanisms but to different extents","volume":"68","author":"Huang","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2147\/JEP.S242964","article-title":"Experimental GABA A receptor agonists and allosteric modulators for the treatment of focal epilepsy","volume":"13","author":"Jankovic","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"B57","first-page":"1121","article-title":"Ro 19-8022, a nonbenzodiazepine partial agonist at benzodiazepine receptors: neuropharmacological profile of a potential anxiolytic","volume":"262","author":"Jenck","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.gim.2021.11.004","article-title":"Structural mapping of GABRB3 variants reveals genotype-phenotype correlations","volume":"24","author":"Johannesen","year":"2022","journal-title":"Genet. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.conb.2013.11.004","article-title":"GABA actions and ionic plasticity in epilepsy","volume":"26","author":"Kaila","year":"2014","journal-title":"Curr. Opin. Neurobiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/s0014-2999(03)02086-7","article-title":"Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice","volume":"474","author":"Kaminski","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/archneur.59.7.1137","article-title":"A splice-site mutation in GABRG2 associated with childhood absence epilepsy and febrile convulsions","volume":"59","author":"Kananura","year":"2002","journal-title":"Arch. Neurol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/nn.4024","article-title":"The human epilepsy mutation GABRG2(Q390X) causes chronic subunit accumulation and neurodegeneration","volume":"18","author":"Kang","year":"2015","journal-title":"Nat. Neurosci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s40263-022-00940-2","article-title":"Benzodiazepines in the management of seizures and status epilepticus: a review of routes of delivery, pharmacokinetics, efficacy, and tolerability","volume":"36","author":"Kienitz","year":"2022","journal-title":"CNS Drugs"},{"key":"B64","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1474-4422(22)00077-1","article-title":"Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Knight","year":"2022","journal-title":"Lancet Neurol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.seizure.2019.03.010","article-title":"Novel variants and phenotypes widen the phenotypic spectrum of GABRG2-related disorders","volume":"69","author":"Komulainen-Ebrahim","year":"2019","journal-title":"Seizure"},{"key":"B66","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/bmj.321.7253.83","article-title":"Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study","volume":"321","author":"Lahat","year":"2000","journal-title":"BMJ"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40263-020-00759-9","article-title":"Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis","volume":"34","author":"Lattanzi","year":"2020","journal-title":"CNS Drugs"},{"key":"B69","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1124\/jpet.119.261222","article-title":"Pharmacological profile of the novel antiepileptic drug candidate padsevonil: characterization in rodent seizure and epilepsy models","volume":"372","author":"Leclercq","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0301-0082(98)00075-6","article-title":"Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action","volume":"58","author":"Loscher","year":"1999","journal-title":"Prog. Neurobiol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/0896-6273(95)90008-x","article-title":"GABA and glutamate depolarize cortical progenitor cells and inhibit DNA synthesis","volume":"15","author":"Loturco","year":"1995","journal-title":"Neuron"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1172\/JCI114877","article-title":"Inactivation of beef brain alpha-ketoglutarate dehydrogenase complex by valproic acid and valproic acid metabolites. Possible mechanism of anticonvulsant and toxic actions","volume":"86","author":"Luder","year":"1990","journal-title":"J. Clin. Invest."},{"key":"B73","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1515\/bmc-2012-0033","article-title":"Neurosteroids and GABAergic signaling in health and disease","volume":"4","author":"Mackenzie","year":"2013","journal-title":"Biomol. Concepts"},{"key":"B74","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.neuron.2017.10.001","article-title":"Getting a handle on Neuropharmacology by targeting receptor-associated proteins","volume":"96","author":"Maher","year":"2017","journal-title":"Neuron"},{"key":"B75","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.yebeh.2004.01.003","article-title":"Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children","volume":"5","author":"Mahmoudian","year":"2004","journal-title":"Epilepsy Behav."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1111\/epi.17336","article-title":"Molecular and clinical descriptions of patients with GABA(A) receptor gene variants (GABRA1, GABRB2, GABRB3, GABRG2): a cohort study, review of literature, and genotype-phenotype correlation","volume":"63","author":"Maillard","year":"2022","journal-title":"Epilepsia"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(21)00247-6","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"B79","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/epi4.12669","article-title":"The efficacy and safety of ganaxolone for the treatment of refractory epilepsy: a meta-analysis from randomized controlled trials","volume":"8","author":"Meng","year":"2023","journal-title":"Epilepsia Open"},{"key":"B80","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.seizure.2021.10.014","article-title":"The neuropathological findings of developmental and epileptic encephalopathy-43 (DEE43) and delineation of a the molecular spectrum of novel case","volume":"93","author":"Mierzewska","year":"2021","journal-title":"Seizure"},{"key":"B81","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","article-title":"Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons","volume":"855","author":"Nakamura","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1600-0404.2010.01474.x","article-title":"Buccal midazolam or rectal diazepam for treatment of residential adult patients with serial seizures or status epilepticus","volume":"124","author":"Nakken","year":"2011","journal-title":"Acta Neurol. Scand."},{"key":"B83","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40263-017-0432-1","article-title":"Stiripentol in the management of epilepsy","volume":"31","author":"Nickels","year":"2017","journal-title":"CNS Drugs"},{"key":"B84","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/bph.14119","article-title":"Pharmacology in translation: the preclinical and early clinical profile of the novel \u03b12\/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865","volume":"175","author":"Nickolls","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/epi.16497","article-title":"Functional characterization of the antiepileptic drug candidate, padsevonil, on GABA(A) receptors","volume":"61","author":"Niespodziany","year":"2020","journal-title":"Epilepsia"},{"key":"B86","doi-asserted-by":"publisher","first-page":"CD002217","DOI":"10.1002\/14651858.CD002217","article-title":"Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures","author":"Nolan","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/nature08503","article-title":"Regulation of cortical microcircuits by unitary GABA-mediated volume transmission","volume":"461","author":"Olah","year":"2009","journal-title":"Nature"},{"key":"B88","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1124\/pr.108.00505","article-title":"International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update","volume":"60","author":"Olsen","year":"2008","journal-title":"Pharmacol. Rev."},{"key":"B89","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.neuropharm.2008.07.045","article-title":"GABA A receptors: subtypes provide diversity of function and pharmacology","volume":"56","author":"Olsen","year":"2009","journal-title":"Neuropharmacology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1021\/acs.jmedchem.9b00322","article-title":"Design and identification of a novel, functionally subtype selective GABA(A) positive allosteric modulator (PF-06372865)","volume":"62","author":"Owen","year":"2019","journal-title":"J. Med. Chem."},{"key":"B91","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1152\/jn.1999.82.2.570","article-title":"Changing properties of GABA(A) receptor-mediated signaling during early neocortical development","volume":"82","author":"Owens","year":"1999","journal-title":"J. Neurophysiol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1111\/epi.17549","article-title":"Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: a \"real-world\" retrospective study","volume":"64","author":"Pena-Ceballos","year":"2023","journal-title":"Epilepsia"},{"key":"B93","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40263-023-01027-2","article-title":"New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System","volume":"37","author":"Perucca","year":"","journal-title":"CNS Drugs"},{"key":"B94","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40263-023-01025-4","volume":"37","author":"Perucca","year":"","journal-title":"New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical DevelopmentCNS Drugs"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1152\/jn.00899.2002","article-title":"Intact synaptic GABAergic inhibition and altered neurosteroid modulation of thalamic relay neurons in mice lacking delta subunit","volume":"89","author":"Porcello","year":"2003","journal-title":"J. Neurophysiol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.1073\/pnas.88.10.4553","article-title":"Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain","volume":"88","author":"Purdy","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B97","doi-asserted-by":"publisher","first-page":"105296","DOI":"10.1016\/j.nbd.2021.105296","article-title":"The K328M substitution in the human GABA(A) receptor gamma2 subunit causes GEFS+ and premature sudden death in knock-in mice","volume":"152","author":"Qu","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"B98","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/j.1528-1167.2006.00497.x","article-title":"Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels","volume":"47","author":"Quilichini","year":"2006","journal-title":"Epilepsia"},{"key":"B99","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/epi4.12656","article-title":"Efficacy and safety of adjunctive padsevonil in adults with drug-resistant focal epilepsy: results from two double-blind, randomized, placebo-controlled trials","volume":"7","author":"Rademacher","year":"2022","journal-title":"Epilepsia Open"},{"key":"B100","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3389\/fncel.2013.00115","article-title":"Role of hormones and neurosteroids in epileptogenesis","volume":"7","author":"Reddy","year":"2013","journal-title":"Front. Cell Neurosci."},{"key":"B101","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.tips.2016.04.003","article-title":"Clinical potential of neurosteroids for CNS disorders","volume":"37","author":"Reddy","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"B102","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.nurt.2009.01.006","article-title":"Neurosteroid replacement therapy for catamenial epilepsy","volume":"6","author":"Reddy","year":"2009","journal-title":"Neurotherapeutics"},{"key":"B103","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.eplepsyres.2010.01.009","article-title":"Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model","volume":"89","author":"Reddy","year":"2010","journal-title":"Epilepsy Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/epi4.12268","article-title":"Brief history of anti-seizure drug development","volume":"3","author":"Rho","year":"2018","journal-title":"Epilepsia Open"},{"key":"B105","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0920-1211(95)00006-v","article-title":"Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial","volume":"21","author":"Richens","year":"1995","journal-title":"Epilepsy Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","article-title":"Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability","volume":"35","author":"Roberti","year":"2021","journal-title":"CNS Drugs"},{"key":"B107","doi-asserted-by":"publisher","first-page":"106592","DOI":"10.1016\/j.eplepsyres.2021.106592","article-title":"Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: a post-hoc analysis of a randomized clinical study","volume":"172","author":"Rosenfeld","year":"2021","journal-title":"Epilepsy Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1124\/jpet.118.252155","article-title":"Intravenously administered ganaxolone blocks diazepam-resistant lithium-pilocarpine-induced status epilepticus in rats: comparison with allopregnanolone","volume":"368","author":"Saporito","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B109","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0140-6736(98)06425-3","article-title":"Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial","volume":"353","author":"Scott","year":"1999","journal-title":"Lancet"},{"key":"B110","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nn1043","article-title":"GABA uptake regulates cortical excitability via cell type-specific tonic inhibition","volume":"6","author":"Semyanov","year":"2003","journal-title":"Nat. Neurosci."},{"key":"B111","doi-asserted-by":"publisher","first-page":"173117","DOI":"10.1016\/j.ejphar.2020.173117","article-title":"Positive allosteric modulation of GABA(A) receptors by a novel antiepileptic drug cenobamate","volume":"879","author":"Sharma","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/s0197-0186(99)00045-5","article-title":"Structure and subunit composition of GABA(A) receptors","volume":"34","author":"Sieghart","year":"1999","journal-title":"Neurochem. Int."},{"key":"B113","doi-asserted-by":"publisher","first-page":"40224","DOI":"10.1074\/jbc.R112.386664","article-title":"Structure, function, and modulation of GABA(A) receptors","volume":"287","author":"Sigel","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B114","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s40263-023-01030-7","article-title":"GABA-Ergic modulators: new therapeutic approaches to premenstrual dysphoric disorder","volume":"37","author":"Sikes-Keilp","year":"2023","journal-title":"CNS Drugs"},{"key":"B115","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1056\/NEJMoa1107494","article-title":"Intramuscular versus intravenous therapy for prehospital status epilepticus","volume":"366","author":"Silbergleit","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/gbb.12321","article-title":"GABA(A) receptor subtype involvement in addictive behaviour","volume":"16","author":"Stephens","year":"2017","journal-title":"Genes Brain Behav."},{"key":"B117","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/15357597231176234","article-title":"Are genetic therapies for epilepsy ready for the clinic?","volume":"23","author":"Street","year":"2023","journal-title":"Epilepsy Curr."},{"key":"B118","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1089\/hum.2022.037","article-title":"Cell-selective adeno-associated virus-mediated SCN1A gene regulation therapy rescues mortality and seizure phenotypes in a Dravet syndrome mouse model and is well tolerated in nonhuman primates","volume":"33","author":"Tanenhaus","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"B119","doi-asserted-by":"publisher","first-page":"6121","DOI":"10.1523\/JNEUROSCI.4733-10.2011","article-title":"Ambient GABA-activated tonic inhibition sharpens auditory coincidence detection via a depolarizing shunting mechanism","volume":"31","author":"Tang","year":"2011","journal-title":"J. Neurosci."},{"key":"B120","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.nbd.2012.10.008","article-title":"Impaired surface \u03b1\u03b2\u03b3 GABA(A) receptor expression in familial epilepsy due to a GABRG2 frameshift mutation","volume":"50","author":"Tian","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"B121","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.nbd.2014.05.013","article-title":"GABAA receptor biogenesis is impaired by the \u03b32 subunit febrile seizure-associated mutation, GABRG2(R177G)","volume":"69","author":"Todd","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1111\/ejn.15133","article-title":"Tonic GABAergic inhibition, via GABAA receptors containing \u03b1\u03b2\u0190 subunits, regulates excitability of ventral tegmental area dopamine neurons","volume":"53","author":"Tossell","year":"2021","journal-title":"Eur. J. Neurosci."},{"key":"B123","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1056\/NEJM199809173391202","article-title":"A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group","volume":"339","author":"Treiman","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuron.2016.06.033","article-title":"GABAergic interneurons in the neocortex: from cellular properties to circuits","volume":"91","author":"Tremblay","year":"2016","journal-title":"Neuron"},{"key":"B125","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/s0920-1211(00)00173-x","article-title":"Tiagabine adjunctive therapy in children with refractory epilepsy: a single-blind dose escalating study","volume":"42","author":"Uldall","year":"2000","journal-title":"Epilepsy Res."},{"key":"B126","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/archneur.55.1.56","article-title":"Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial","volume":"55","author":"Uthman","year":"1998","journal-title":"Arch. Neurol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1111\/epi.17343","article-title":"Intravenous ganaxolone for the treatment of refractory status epilepticus: results from an open-label, dose-finding, phase 2 trial","volume":"63","author":"Vaitkevicius","year":"2022","journal-title":"Epilepsia"},{"key":"B128","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0304-3940(93)90707-r","article-title":"Cl-channels are randomly activated by continuous GABA secretion in cultured embryonic rat hippocampal neurons","volume":"155","author":"Valeyev","year":"1993","journal-title":"Neurosci. Lett."},{"key":"B129","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1152\/jn.01224.2007","article-title":"Cell type-specific GABA A receptor-mediated tonic inhibition in mouse neocortex","volume":"100","author":"Vardya","year":"2008","journal-title":"J. Neurophysiol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ng0501-49","article-title":"Mutant GABA(A) receptor gamma2-subunit in childhood absence epilepsy and febrile seizures","volume":"28","author":"Wallace","year":"2001","journal-title":"Nat. Genet."},{"key":"B131","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.eplepsyres.2019.04.006","article-title":"The therapeutic effect of stiripentol in Gabrg2(+\/Q390X) mice associated with epileptic encephalopathy","volume":"154","author":"Warner","year":"2019","journal-title":"Epilepsy Res."},{"key":"B132","doi-asserted-by":"publisher","first-page":"173321","DOI":"10.1016\/j.pbb.2021.173321","article-title":"The imidazodiazepine, KRM-II-81: an example of a newly emerging generation of GABAkines for neurological and psychiatric disorders","volume":"213","author":"Witkin","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.119.261149","article-title":"Pharmacological profile of the novel antiepileptic drug candidate padsevonil: interactions with synaptic vesicle 2 proteins and the GABA(A) receptor","volume":"372","author":"Wood","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1341472\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T05:49:44Z","timestamp":1708494584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1341472\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":134,"alternative-id":["10.3389\/fphar.2024.1341472"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1341472","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"article-number":"1341472"}}